HC Wainwright Predicts Stronger Earnings for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Equities researchers at HC Wainwright raised their FY2025 EPS estimates for shares of Zenas BioPharma in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($3.44) per share for the year, up from their previous estimate of ($3.47). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($1.06) EPS, Q2 2026 earnings at ($1.06) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($3.47) EPS, FY2027 earnings at ($2.85) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($2.34) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

A number of other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zenas BioPharma in a report on Thursday, October 30th. Citigroup lifted their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Jefferies Financial Group reissued a “buy” rating and set a $52.00 target price on shares of Zenas BioPharma in a research report on Monday, October 27th. Morgan Stanley lifted their price target on shares of Zenas BioPharma from $34.00 to $37.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 price target (up from $40.00) on shares of Zenas BioPharma in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Zenas BioPharma Trading Up 0.9%

ZBIO opened at $36.21 on Monday. Zenas BioPharma has a 12 month low of $5.83 and a 12 month high of $37.89. The stock has a fifty day moving average price of $25.89 and a 200-day moving average price of $17.47. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -5.12 and a beta of -1.51. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37.

Insider Transactions at Zenas BioPharma

In related news, Director Patrick G. Enright purchased 105,265 shares of the firm’s stock in a transaction on Thursday, October 9th. The stock was acquired at an average price of $19.00 per share, with a total value of $2,000,035.00. Following the completion of the acquisition, the director owned 1,832,669 shares in the company, valued at approximately $34,820,711. This represents a 6.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Hongbo Lu acquired 263,160 shares of the stock in a transaction dated Tuesday, October 7th. The shares were bought at an average price of $19.00 per share, with a total value of $5,000,040.00. Following the completion of the purchase, the director directly owned 321,983 shares of the company’s stock, valued at approximately $6,117,677. This trade represents a 447.38% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 923,035 shares of company stock worth $17,628,163 over the last ninety days. 16.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its stake in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after purchasing an additional 703,838 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after purchasing an additional 170,546 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the period. Invesco Ltd. purchased a new stake in Zenas BioPharma in the third quarter valued at approximately $3,237,000. Finally, Millennium Management LLC purchased a new stake in Zenas BioPharma in the third quarter valued at approximately $1,595,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.